公开(公告)号：US20080075716A1

公开(公告)日：2008-03-27

申请号：US11928221

申请日：2007-10-30

申请人： Jan Nilsson ,  Roland Carlsson ,  Jenny Bengtsson ,  Leif Strandberg

发明人： Jan Nilsson ,  Roland Carlsson ,  Jenny Bengtsson ,  Leif Strandberg

IPC分类号： A61K39/395 ,  A61P9/10 ,  C07K16/18

CPC分类号： C07K14/775 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/622

摘要： The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization.

摘要翻译： 本发明涉及用于治疗或预防动脉粥样硬化的被动免疫，其使用针对至少一种载脂蛋白B的氧化片段的分离的人抗体制造用于通过被动免疫治疗或预防性治疗动脉粥样硬化的药物组合物，以及 制备这种抗体的方法，以及使用这种抗体治疗哺乳动物，优选人的方法以提供被动免疫。

公开(公告)号：US6159690A

公开(公告)日：2000-12-12

申请号：US98287

申请日：1998-06-16

申请人： Carl Arne Krister Borrebaeck ,  Ulf Hans Eskil Soderlind ,  Rebecka Ingrid Camilla Ottosson

发明人： Carl Arne Krister Borrebaeck ,  Ulf Hans Eskil Soderlind ,  Rebecka Ingrid Camilla Ottosson

IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K38/43 ,  A61K39/395 ,  C12N15/10 ,  C12P21/02 ,  C12Q1/68 ,  C40B40/02 ,  C12P19/34

CPC分类号： C40B40/02 ,  C12N15/1027 ,  C12N15/1037 ,  C12Q1/6811 ,  C12Q1/6858 ,  C12Q2521/319

摘要： The present invention relates to a method for in vitro evolution of protein function. In particular, the method relates to the shuffling of nucleotide segments obtained from exonuclease digestion. The present inventors have shown that polynucleotide fragments derived from a parent polynucleotide sequence digested with an exonuclease can be combined to generate a polynucleotide sequence which encodes for a polypeptide having desired characteristics. This method may be usefully applied to the generation of new antibodies or parts thereof having modified characteristics as compared to the parent antibody.

摘要翻译： 本发明涉及蛋白质功能体外进化的方法。 特别地，该方法涉及从外切核酸酶消化获得的核苷酸片段的改组。 本发明人已经显示衍生自用外切核酸酶消化的亲代多核苷酸序列的多核苷酸片段可以组合以产生编码具有所需特征的多肽的多核苷酸序列。 与母体抗体相比，该方法可有效地应用于具有修饰特征的新抗体或其部分的产生。

公开(公告)号：US6027930A

公开(公告)日：2000-02-22

申请号：US875069

申请日：1997-08-22

申请人： Carl A. K. Borrebaeck

发明人： Carl A. K. Borrebaeck

IPC分类号： G01N33/569 ,  C12N7/00 ,  C12N7/01 ,  C12N15/09 ,  C12N15/10 ,  C12Q1/68 ,  C12Q1/70 ,  C40B40/02 ,  G01N33/53

CPC分类号： C40B40/02 ,  C12N15/1037

摘要： An improved method for selecting a molecule such as an antibody, antigen, peptide, protein or fragment thereof and its encoding sequence, which molecule is expressed together with a phage coat protein on the phages surface. The improvement is achieved through a new mutant filamentous helper phage which has retained the gene III promoter, whereas the gene III encoding sequence is deleted. Amplification of phage titer of 10.sup.6 times were achieved in M13-derived phages, when used for the selection of specific antibody.

摘要翻译： PCT No.PCT / SE96 / 00030 Sec。 371日期1997年8月22日 102（e）日期1997年8月22日PCT 1996年1月15日PCT公布。 WO96 / 22393 PCT出版物 日期1996年7月25日改进的选择抗体，抗原，肽，蛋白质或其片段等分子及其编码序列的方法，该分子与噬菌体表面上的噬菌体外壳蛋白一起表达。 通过保留了基因III启动子的新的突变丝状辅助噬菌体实现了改进，而缺失了基因III编码序列。 当用于选择特异性抗体时，在M13衍生的噬菌体中实现了106次噬菌体滴度的扩增。

公开(公告)号：US20240301070A1

公开(公告)日：2024-09-12

申请号：US18008141

申请日：2021-06-04

申请人： BIOINVENT INTERNATIONAL AB

发明人： Björn FRENDÉUS ,  Linda MÅRTENSSON ,  Ingrid TEIGE ,  Ingrid KARLSSON

IPC分类号： C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61P35/00

CPC分类号： C07K16/283 ,  A61K9/0019 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/545

摘要： The present invention generally relates to combinations for use in therapeutic systems and antibody dosage regimens, and uses thereof. Also described herein is a model for predicting if a therapeutic antibody binding to a human target will be associated with a tolerability issue in connection with intravenous administration and/or for predicting if pre-treatment, altered administration route or modification of the antibody can prevent a tolerability issue associated with intravenous administration to a human of the therapeutic antibody. The model comprises administering the antibody intravenously or intraperitoneally to mice and observing the mice immediately after the administration for any transient display of the macroscopic symptoms isolation and decreased activity. The model may also comprise administration of a pre-treatment in combination with administration of the antibody, administration of the therapeutic antibody by a route of administration other than intravenous or intraperitoneal administration or administration of a modified format of the antibody to mice and observing the mice immediately after such administration for any transient display of the macroscopic symptoms isolation and decreased activity and comparing this with the transient display of the macroscopic symptoms isolation and decreased activity after the intravenous or intraperitoneal administration of the unmodified antibody without pre-treatment.

公开(公告)号：US20240092912A1

公开(公告)日：2024-03-21

申请号：US18281530

申请日：2022-03-09

申请人： BIOINVENT INTERNATIONAL AB ,  UNIVERSITY OF SOUTHAMPTON

发明人： Björn FRENDÉUS ,  Linda MÅRTENSSON ,  Ingrid TEIGE ,  Mark CRAGG ,  Robert OLDHAM ,  Stephen BEERS ,  Ali ROGHANIAN

IPC分类号： C07K16/28 ,  A61P35/00

CPC分类号： C07K16/283 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/507

摘要： The present invention generally relates to antibody combinations and uses thereof.

公开(公告)号：US20230070339A1

公开(公告)日：2023-03-09

申请号：US17799240

申请日：2021-02-12

申请人： University of Southampton ,  BIOINVENT INTERNATIONAL AB

发明人： Björn FRENDÉUS ,  All Roghanian ,  Mark GRAGG

IPC分类号： C07K16/28 ,  A61P37/06

摘要： Described are anti-LILRB3 antibody molecules, such as agonistic anti-LILRB3 antibody molecules for use in treatment of graft rejection or autoimmunity via reprograming of human myeloid cells. Described are also specific anti-LILRB3 antibody molecules and use of such antibody molecules in medicine, for example in treatment of graft rejection, autoimmune disorders or inflammatory disorders.

公开(公告)号：US07943744B2

公开(公告)日：2011-05-17

申请号：US12097193

申请日：2006-12-08

申请人： Björn Frendéus ,  Roland Carlsson ,  Anne-Christine Carlsson, legal representative

发明人： Björn Frendéus ,  Roland Carlsson

IPC分类号： C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  A61K39/00 ,  G01N33/53

CPC分类号： C07K16/2803 ,  A61K2039/505 ,  C07K16/2821 ,  C07K16/2833 ,  C07K16/4283 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/75 ,  C07K2317/94

摘要： The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce apoptosis of the target cell. There is also provided methods of and pharmaceutical compositions for apoptosis induction and uses thereof.

摘要翻译： 本发明提供了结合分子，包括选择性结合靶细胞的细胞表面抗原的抗体分子，并且其中结合分子在细胞表面抗原结合时诱导靶细胞凋亡。 还提供了用于凋亡诱导的方法和药物组合物及其用途。

公开(公告)号：US5712089A

公开(公告)日：1998-01-27

申请号：US640792

申请日：1996-10-07

申请人： Carl A. K. Borrebaeck ,  Marta Duenas

发明人： Carl A. K. Borrebaeck ,  Marta Duenas

IPC分类号： C12N15/09 ,  C07K14/005 ,  C07K16/00 ,  C07K16/08 ,  C12N7/00 ,  C12N7/01 ,  C12N15/10 ,  C12P21/04 ,  C40B40/02 ,  C12Q1/07 ,  C12Q1/02 ,  G01N33/53

CPC分类号： C40B40/02 ,  C12N15/1037

摘要： A method for selecting a molecule such as an antibody, antigen, peptide, protein or fragment thereof, which molecule is expressed together with a phage coat protein on the phage's surface. The method is characterised by linking phage replication to recognition of the molecule on the surface of the phage. The linkage can be achieved by use of a fusion protein between phage protein 3 and a specific binding ligand for the molecule.

摘要翻译： PCT No.PCT / SE94 / 01166 Sec。 371日期1996年10月7日第 102（e）日期1996年10月7日PCT 1994年12月5日PCT PCT。 出版物WO95 / 16027 日期：1995年6月15日一种选择抗体，抗原，肽，蛋白质或其片段等分子的方法，该分子与噬菌体表面上的噬菌体外壳蛋白一起表达。 该方法的特征在于将噬菌体复制连接到噬菌体表面上的分子识别。 可以通过使用噬菌体蛋白3和分子的特异性结合配体之间的融合蛋白来实现连接。

公开(公告)号：US10351970B2

公开(公告)日：2019-07-16

申请号：US15055814

申请日：2016-02-29

申请人： BioInvent International AB

发明人： Björn Frendéus

IPC分类号： G01N33/68 ,  G01N33/554 ,  C12N15/10 ,  C40B30/04

摘要： The present invention relates to screening methods and, in particular, to methods of screening anti-ligand libraries for identifying anti-ligands specific for differentially and/or infrequently expressed ligands. The method comprises the steps of providing a library of anti-ligands: providing a first subtractor ligand; providing a second target ligand; determining the amount of the first and second target ligands using one or more equations derived from the universal law of mass action; providing the determined amount of a first subtractor ligand; providing the determined amount of a second target ligand; providing separation means capable of use to isolate anti-ligand bound to the second target ligand from anti-ligand bound to the first subtractor ligand; exposing the library of to the first and second target ligands to permit binding of anti-ligands to ligands; and using the separation means to isolate the anti-ligand bound to second target ligand.

公开(公告)号：US10191049B2

公开(公告)日：2019-01-29

申请号：US14346432

申请日：2012-09-20

申请人： BioInvent International AB

发明人： Bjorn Frendeus ,  Jenny Mattsson

IPC分类号： G01N33/48 ,  G01N33/566 ,  G01N33/68 ,  C12N15/10 ,  G06G7/58

摘要： The present invention relates to improved screening methods and, in particular, to methods of screening anti-ligand libraries for identifying anti-ligands specific for differentially and/or infrequently expressed ligands.